The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms

Cancer

Volumn 119, Issue 5, 2013, Pages 1080-1088

  Stoyanova, Radka ^a,b   Pahlajani, Niraj H ^b   Egleston, Brian L ^b   Buyyounouski, Mark K ^b   Chen, David Y T ^c   Horwitz, Eric M ^b   Pollack, Alan ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c Florida Radiation Oncology Group   (United States)

Author keywords

androgen deprivation therapy; nomogram; prostate cancer; radiation treatment

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NOMOGRAM; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE ESCALATION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL;

EID: 84874233328     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27857     Document Type: Article

References (20)

1. Kuban DA, Tucker SL, Dong L, Starkschall G, et al. Long-term results of the M. D Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 67-74.
2. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294: 1233-1239.
3. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360: 103-106.
4. D'Amico AV, Manola J, Loffredo M, et al. Six-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-827.
5. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008; 26: 2497-2504.
6. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360: 2516-2527.
7. Williams SG, Buyyounouski MK, Pickles T, et al. Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performance. Int J Radiat Oncol Biol Phys. 2008; 70: 1169-1175.
8. Horwitz EM, Hanlon AL, Pinover WH, et al. Defining the optimal radiation dose with 3-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001; 92: 1281-1287.
9. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006; 64: 518-526.
10. D'Ambrosio DJ, Hanlon AL, Al-Saleem T, et al. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 1082-1087.
11. Harrell FE,. Regression Modeling Strategies. New York: Springer; 2001.
12. Ruan PK, Gray RJ,. Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med. 2008; 27: 5709-5724.
13. Kattan MW, Heller G, Brennan MF,. A competing-risks nomogram for sarcoma-specific death following local recurrence. Stat Med. 2003; 22: 3515-3525.
14. Gray RJ,. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1143.
15. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90: 766-771.
16. Bismar TA, Humphrey P, Vollmer RT,. Information content of 5 nomograms for outcomes in prostate cancer. Am J Clin Pathol. 2007; 128: 803-807.
17. Freedland SJ, Csathy GS, Dorey F, et al. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol. 2002; 167 (2 pt 1): 516-520.
18. D'Amico AV, Keshaviah A, Manola J, et al. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002; 53: 581-587.
19. Stamey TA, Yemoto CM, McNeal JE, et al. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol. 2000; 163: 1155-1160.
20. Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011; 79: 1310-1317.